Early versus late oseltamivir treatment in severely ill patients with 2009 pandemic influenza A (H1N1): speed is life
- PMID: 21406435
- DOI: 10.1093/jac/dkr090
Early versus late oseltamivir treatment in severely ill patients with 2009 pandemic influenza A (H1N1): speed is life
Abstract
The need for early antimicrobial therapy is well established for life-threatening bacterial and fungal infections including meningitis and sepsis/septic shock. However, a link between the outcome of serious viral infections and delays in antiviral therapy is not as well recognized. Recently, with the occurrence of the influenza A/H1N1 pandemic of 2009, a large body of data regarding this issue has become available. Studies analysing data from this pandemic have consistently shown that delays in initiation of antiviral therapy following symptom onset are significantly associated with disease severity and death. Optimal survival and minimal disease severity appear to result when antivirals are started as soon as possible after symptom onset.
Similar articles
-
Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A.J Antimicrob Chemother. 2011 May;66(5):1140-9. doi: 10.1093/jac/dkq511. Epub 2011 Jan 7. J Antimicrob Chemother. 2011. PMID: 21385717
-
Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v.Scand J Infect Dis. 2011 Jul;43(6-7):495-503. doi: 10.3109/00365548.2011.556144. Epub 2011 Feb 10. Scand J Infect Dis. 2011. PMID: 21309638
-
2009 Influenza A H1N1 infections: delays in starting treatment with oseltamivir were associated with a more severe disease.Pediatr Infect Dis J. 2011 Jul;30(7):622-5. doi: 10.1097/INF.0b013e3182093397. Pediatr Infect Dis J. 2011. PMID: 21200359
-
The use of antiviral agents for the management of severe influenza.Crit Care Med. 2010 Apr;38(4 Suppl):e43-51. doi: 10.1097/CCM.0b013e3181c85229. Crit Care Med. 2010. PMID: 19935416 Review.
-
Treatment options for 2009 H1N1 influenza: evaluation of the published evidence.Int J Antimicrob Agents. 2010 May;35(5):421-30. doi: 10.1016/j.ijantimicag.2010.01.006. Epub 2010 Feb 24. Int J Antimicrob Agents. 2010. PMID: 20185273 Review.
Cited by
-
Debate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza.Emerg Infect Dis. 2016 Jun;22(6):949-55. doi: 10.3201/eid2206.151037. Emerg Infect Dis. 2016. PMID: 27191818 Free PMC article.
-
Traditional Chinese Medicine Injections Combined With Oseltamivir for Influenza: Systematic Review and Network Meta-Analysis.Front Pharmacol. 2022 Jul 22;13:848770. doi: 10.3389/fphar.2022.848770. eCollection 2022. Front Pharmacol. 2022. PMID: 35935865 Free PMC article.
-
Impact of the 2009/2010 influenza A (H1N1) pandemic on trends in influenza hospitalization, diagnostic testing, and treatment.Influenza Other Respir Viruses. 2012 Sep;6(5):305-8. doi: 10.1111/j.1750-2659.2011.00303.x. Epub 2011 Nov 16. Influenza Other Respir Viruses. 2012. PMID: 22085222 Free PMC article.
-
Safety and efficacy of tocilizumab in the treatment of severe acute respiratory syndrome coronavirus-2 pneumonia: A retrospective cohort study.Indian J Med Microbiol. 2020 Jan-Mar;38(1):117-123. doi: 10.4103/ijmm.IJMM_20_298. Indian J Med Microbiol. 2020. PMID: 32719218 Free PMC article.
-
Comprehensive Analysis of Severe Viral Infections of Respiratory Tract admitted to PICUs during the Winter Season in Turkey.Indian J Crit Care Med. 2019 Jun;23(6):263-269. doi: 10.5005/jp-journals-10071-23177. Indian J Crit Care Med. 2019. PMID: 31435144 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical